Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Draffan

Alistair Draffan, St Kilda East, Victoria AU

Patent application numberDescriptionPublished
20100291031BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS - The invention relates to the use of bicyclic nucleosides and nucleotides based on formula (II) for the treatment of infectious diseases, and in particular, viral infections. 11-18-2010

Alistair George Draffan, Victoria AU

Patent application numberDescriptionPublished
20100021458POLYCYCLIC AGENTS FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTIONS - The present invention relates to polycyclic antiviral compounds, and salts thereof, methods for their preparation and compositions containing them, and the use of the compounds and composition in the treatment of viral infections.01-28-2010
20100035836BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS - The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.02-11-2010

Alistair George Draffan, St Kilda East AU

Patent application numberDescriptionPublished
20090004138Bicyclic Nucleosides and Nucleotides as Therapeutic Agents - The invention relates to the use of bicyclic nucleosides and nucleotides based on formula (II) for the treatment of infectious diseases, and in particular, viral infections.01-01-2009

Alistair George Draffan US

Patent application numberDescriptionPublished
20110207728COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS - The present invention relates to compounds of formula (I)08-25-2011

Alistair George Draffan, Notting Hill AU

Patent application numberDescriptionPublished
20120135998COMPOUNDS FOR TREATING RESPIRATORY SYNCYTIAL VIRUS INFECTIONS - The present invention relates to compounds of formula (I), racemates, isomers and/or salts thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds.05-31-2012